Compare · NVO vs PHVS
NVO vs PHVS
Side-by-side comparison of Novo Nordisk A/S (NVO) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 91.5x PHVS ($2.43B).
- Over the past year, NVO is down 22.5% and PHVS is up 48.3% - PHVS leads by 70.8 points.
- PHVS has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for PHVS).
- Company
- Novo Nordisk A/S
- Pharvaris N.V.
- Price
- $50.31-2.25%
- $34.91+3.67%
- Market cap
- $222.81B
- $2.43B
- 1M return
- +15.47%
- +10.98%
- 1Y return
- -22.53%
- +48.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 14
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PHVS
- Chief Executive Officer Modig Berndt sold $80,154 worth of shares (2,292 units at $34.97) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 132,917 units (SEC Form 4)
- Wells Fargo initiated coverage on Pharvaris N.V. with a new price target
- Chief Medical Officer Lu Peng covered exercise/tax liability with 226 shares, decreasing direct ownership by 0.34% to 65,405 units (SEC Form 4) (tax withholding)
- SEC Form 144 filed by Pharvaris N.V.
- Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
- Director Schikan Johannes Gerardus Christiaan Petrus sold $1,331,496 worth of shares (37,600 units at $35.41) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 315,167 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 38,472 shares at a strike of $6.85 and sold $2,695,452 worth of shares (76,172 units at $35.39) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 58,750 units (SEC Form 4)
- Chief Early Development Lesage Anne exercised 2,300 shares at a strike of $4.73 and sold $161,560 worth of shares (4,600 units at $35.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Schikan Johannes Gerardus Christiaan Petrus sold $84,250 worth of shares (2,400 units at $35.10) as part of a pre-agreed trading plan, decreasing direct ownership by 0.68% to 352,767 units (SEC Form 4)
- Chief Medical Officer Lu Peng exercised 29,700 shares at a strike of $2.59 and sold $1,018,832 worth of shares (29,700 units at $34.30) as part of a pre-agreed trading plan (SEC Form 4)